Lawrence Fong, MD

Professor
Department of Medicine
lfong@medicine.ucsf.edu

Our lab focuses upon the interactions between dendritic cells (DC) and T cells in disease states such as cancer and autoimmunity. DC represent a set bone marrow-derived antigen presenting cells that are uniquely capable of initiating or modulating T cell immunity. By studying how difference types of DC repond to different stimuli (e.g., viruses, bacteria), we hope to understand how DC can coordinate difference immune outcomes in response to different pathogens and disease states.

We also develop approaches to exploit DC as a platform for antigen-specific immune modulation in vivo in both animal models and humans. We have shown that antigen loaded DC can serve as therapeutic vaccine in cancer patients. Moreover, in vivo expansion of CD8 T cells identified with MHC/peptide tetramers following vaccination can correlate with tumor responses. By identifying the dynamics of antigen specific T cells and their capacity to develop immunologic memory, we hope to develop improved strategies in tumor immunotherapy. Future work will also focus upon understanding how altered peptide ligands or altered forms of self-antigens can enhance the immune response to tumor-associated self-antigens.

Primary Thematic Area: 
Immunology
Secondary Thematic Area: 
Cancer Biology & Cell Signaling
Research Summary: 
Immunobiology of Dendritic Cells in Disease

Websites

Publications: 

Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial.

Pediatrics

Cabana MD, McKean M, Caughey AB, Fong L, Lynch S, Wong A, Leong R, Boushey HA, Hilton JF

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Clinical genitourinary cancer

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF

Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Cell

Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG